Search Within

Isabelle C Riviere

  1. "Blood"
  2. "Xiuyan Wang"
  3. "Brigitte Senechal"
Formats
  1. Meeting Abstract (7)
  2. Journal Article (3)
Groups
  1. Department of Medicine (10)
  2. Hematologic Malignancies, Division of (10)
  3. Adult Leukemia (9)
  4. Center for Hematologic Malignancies (9)
  5. GSK Faculty (9)
  6. Hematologic Malignancies Research (9)

More Groups

People
  1. Brigitte Senechal (10)
  2. Xiuyan Wang (10)
  3. Jae Park (9)
  4. Renier Brentjens (8)
  5. Michel Sadelain (7)
  6. Claudia Diamonte (5)

More People

Years
  1. 2022 (1)
  2. 2021 (3)
  3. 2020 (1)
  4. 2019 (2)
  5. 2018 (2)
  6. 2016 (1)
Publications
  1. Blood (10)
Publishers
  1. American Society of Hematology (10)

Results (10)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase I study of CD19-targeted 19(T2)28z1XX CAR T cells in adult patients with relapsed or refractory diffuse large B-cell lymphoma
    Meeting Abstract

    Park, J. H.; Palomba, M. L.; Rivière, I.; Sikder, D. S.; Senechal, B.; Wang, X.; Bermudez, V. P.; Cathcart, E. R.; Liotta, K.; Joseph, J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Clinical manufacture of FT819: Use of a clonal multiplexed-engineered master induced pluripotent stem cell line to mass produce off-the-shelf CAR T-cell therapy
    Meeting Abstract

    Yuan, X.; Clarke, R.; Lai, Y. S.; Chang, C. W.; Yang, B. H.; Hsia, G.; Abujarour, R.; Lee, T.; van der Stegen, S.; Shaked, H.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Phase I first-in-class trial of MCARH109, a G protein coupled receptor class C group 5 member D (GPRC5D) targeted CAR T cell therapy in patients with relapsed or refractory multiple myeloma
    Meeting Abstract

    Mailankody, S.; Diamonte, C.; Fitzgerald, L.; Kane, P.; Wang, X.; Sikder, D. S.; Senechal, B.; Bermudez, V. P.; Frias, D.; Morgan, J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy
    Journal Article

    Wudhikarn, K.; Flynn, J. R.; Rivière, I.; Gönen, M.; Wang, X.; Senechal, B.; Curran, K. J.; Roshal, M.; Maslak, P. G.; Geyer, M. B.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • A phase I study of CD19-targeted 19(T2)28z1xx CAR T cells in adult patients with relapsed or refractory B-cell malignancies
    Meeting Abstract

    Park, J. H.; Riviere, I.; Sikder, D. S.; Bermudez, V. P.; Senechal, B.; Wang, X.; Auchincloss, T. H.; Diamonte, C.; Halton, E.; Palomba, M. L.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL
    Journal Article

    Curran, K. J.; Margossian, S. P.; Kernan, N. A.; Silverman, L. B.; Williams, D. A.; Shukla, N.; Kobos, R.; Forlenza, C. J.; Steinherz, P.; Prockop, S.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma
    Journal Article

    Sauter, C. S.; Senechal, B.; Rivière, I.; Ni, A.; Bernal, Y.; Wang, X.; Purdon, T.; Hall, M.; Singh, A. N.; Szenes, V. Z.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • A phase I first-in-human clinical trial of CD19-targeted 19-28z/4-1BBL "armored" CAR T cells in patients with relapsed or refractory NHL and CLL including Richter's transformation
    Meeting Abstract

    Park, J. H.; Palomba, M. L.; Batlevi, C. L.; Riviere, I.; Wang, X.; Senechal, B.; Furman, R. R.; Bernal, Y.; Hall, M.; Pineda, J.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Clinical responses and pharmacokinetics of MCARH171, a human-derived BCMA targeted CAR T cell therapy in relapsed/refractory multiple myeloma: Final results of a phase I clinical trial
    Meeting Abstract

    Mailankody, S.; Ghosh, A.; Staehr, M.; Purdon, T. J.; Roshal, M.; Halton, E.; Diamonte, C.; Pineda, J.; Anant, P.; Bernal, Y.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Implications of concurrent ibrutinib therapy on CAR T-cell manufacturing and phenotype and on clinical outcomes following CD19-targeted CAR T-cell administration in adults with relapsed/refractory CLL
    Meeting Abstract

    Geyer, M. B.; Park, J. H.; Riviere, I.; Senechal, B.; Wang, X.; Purdon, T. J.; Sadelain, M. W.; Brentjens, R. J.
    Blood (2016)

    Fulltext@MSK | Save